Keywords
acute myocardial infarction, cardiovascular diseases, NT-proBNP, ST2, heart failure
How to Cite
Labinska, O., Halkevych, M., BihunІ., & Khamuliak, K. (2024). The significance of NT-proBNP and ST2 biomarkers in predicting the risk of complications after acute myocardial infarction (literature review). The Practitioner, (3), 18-23. Retrieved from https://plr.com.ua/index.php/journal/article/view/824
Abstract
For the purpose of diagnosis and prediction the course of cardiovascular diseases, in addition to the determination of cardiac troponins, new biomarkers of myocardial damage are increasingly used in cardiology practice, which detect the presence of ischemia, inflammatory activity, myocardial distention, and interstitial remodeling. The change in cardiovascular homeostasis in patients with acute myocardial infartion reflects an inflammatory reaction that occurs under conditions of hemodynamic stress; this is a basis of early and long-term postinfarction remodeling of the left ventricle. This article describes the role of NT-proBNP and ST2 biomarkers in risk stratification of cardiovascular complications in the postinfarction period.
References
1. Павлов СВ, Бурлака КА. Сучасні молекулярно-генетичні маркери в діагностиці та скринінгу ефективності проведеної терапії захворювань серцево-судинної системи. Вісник проблем біології і медицини. 2018;2(144):49–55.
2. Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Simic D, Radovanovic S, Simic T. Novel Biomarkers of Heart Failure. Adv Clin Chem. 2017;79:93-152. doi: 10.1016/bs.acc.2016.09.002. Epub 2016 Nov 3. PMID: 28212715.
3. Wang X, Zhang F, Zhang C, Zheng L, Yang J. The Biomarkers for Acute Myocardial Infarction and Heart Failure. Biomed Res Int. 2020 Jan 17;2020:2018035. doi: 10.1155/2020/2018035. PMID: 32016113; PMCID: PMC6988690.
4. Daniels LB, Maisel A. B-type natriuretic peptide : time to incorporate natriuretic peptides in our practice. J. Cardiovas. Med. 2006;.7: 414–415.
5. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998; 339: 321-328.
6. York M, Gupta D, Reynolds C, Farber-Eger E, Wells Q, Bachmann K, Xu M, Harrell F Jr, Wang T. B-Type Natriuretic Peptide Levels and Mortality in Patients With and Without Heart Failure. J Am Coll Cardiol. 2018 May 15;71(19):2079-2088. doi: 10.1016/j.jacc.2018.02.071. PMID: 29747827; PMCID: PMC5951190.
7. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004 Mar 15;6(3):257–60. doi: 10.1016/j.ejheart.2003.12.015. PMID: 14987573.
8. Luchner A, Hengstenberg C, Lowel H, Trawinski J, Baumann M, Riegger G, Schunkert H, Holmer S. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension. 2002;39:99-104. https://doi.org/10.1161/hy0102.100537.
9. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and Nt-proBNP in clinical routine. Heart. 2006;92:843–9. doi: 10.1136/hrt.2005.071233. PMID: 16698841; PMCID: PMC1860679.
10. Алієва АМ, Резник ЄВ, Гасанова ЕТ, Жбанів ІВ, Нікітін ІГ. Клінічне значення визначення біомаркерів крові у хворих з хронічною серцевою недостатністю. Архів внутрішньої медицини. 2018;8(5):333–45.
11. Morita E, Yasue H, Yoshimura M et al. Increased plasma levels of brain natriuretic peptide concentrations in patients with acute myocardial infarction. Circulation. 2003; 88:82–91. doi: 10.1161/01.cir.88.1.82. PMID: 8319360.
12. Ogawa A, Seino Y, Yamashita T et al. Difference in elevation of N-terminal proBNP and conventional cardiac markers between patients with ST elevation vs non-ST-elevation acute coronary syndrome. Circulation. 2006:70;1372–1378.
13. Seino Y, Ogawa А, Yamashita Т, Fukushima M, Ogata K, Fukumoto H, et al. Application of NT-proBNP and BNP measurements in cardiac care: A more discerning marker for the detection and evaluation of heart failure. Eur. J. Heart Failure. 2004;6:295- 300.
14. Tilea I, Varga A, Serban RC. Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction — Promises and Challenges. Diagnostics. 2021; 11(5):881. https://doi.org/10.3390/diagnostics11050881.
15. Sahinarslan А, Cengel А, Okyay К, et al. B-type natriuretic peptide and extent of lesion on coronary angiography in stable coronary artery disease. Cor. Art Dis. 2005;16:225-29.
2. Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Simic D, Radovanovic S, Simic T. Novel Biomarkers of Heart Failure. Adv Clin Chem. 2017;79:93-152. doi: 10.1016/bs.acc.2016.09.002. Epub 2016 Nov 3. PMID: 28212715.
3. Wang X, Zhang F, Zhang C, Zheng L, Yang J. The Biomarkers for Acute Myocardial Infarction and Heart Failure. Biomed Res Int. 2020 Jan 17;2020:2018035. doi: 10.1155/2020/2018035. PMID: 32016113; PMCID: PMC6988690.
4. Daniels LB, Maisel A. B-type natriuretic peptide : time to incorporate natriuretic peptides in our practice. J. Cardiovas. Med. 2006;.7: 414–415.
5. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998; 339: 321-328.
6. York M, Gupta D, Reynolds C, Farber-Eger E, Wells Q, Bachmann K, Xu M, Harrell F Jr, Wang T. B-Type Natriuretic Peptide Levels and Mortality in Patients With and Without Heart Failure. J Am Coll Cardiol. 2018 May 15;71(19):2079-2088. doi: 10.1016/j.jacc.2018.02.071. PMID: 29747827; PMCID: PMC5951190.
7. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004 Mar 15;6(3):257–60. doi: 10.1016/j.ejheart.2003.12.015. PMID: 14987573.
8. Luchner A, Hengstenberg C, Lowel H, Trawinski J, Baumann M, Riegger G, Schunkert H, Holmer S. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension. 2002;39:99-104. https://doi.org/10.1161/hy0102.100537.
9. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and Nt-proBNP in clinical routine. Heart. 2006;92:843–9. doi: 10.1136/hrt.2005.071233. PMID: 16698841; PMCID: PMC1860679.
10. Алієва АМ, Резник ЄВ, Гасанова ЕТ, Жбанів ІВ, Нікітін ІГ. Клінічне значення визначення біомаркерів крові у хворих з хронічною серцевою недостатністю. Архів внутрішньої медицини. 2018;8(5):333–45.
11. Morita E, Yasue H, Yoshimura M et al. Increased plasma levels of brain natriuretic peptide concentrations in patients with acute myocardial infarction. Circulation. 2003; 88:82–91. doi: 10.1161/01.cir.88.1.82. PMID: 8319360.
12. Ogawa A, Seino Y, Yamashita T et al. Difference in elevation of N-terminal proBNP and conventional cardiac markers between patients with ST elevation vs non-ST-elevation acute coronary syndrome. Circulation. 2006:70;1372–1378.
13. Seino Y, Ogawa А, Yamashita Т, Fukushima M, Ogata K, Fukumoto H, et al. Application of NT-proBNP and BNP measurements in cardiac care: A more discerning marker for the detection and evaluation of heart failure. Eur. J. Heart Failure. 2004;6:295- 300.
14. Tilea I, Varga A, Serban RC. Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction — Promises and Challenges. Diagnostics. 2021; 11(5):881. https://doi.org/10.3390/diagnostics11050881.
15. Sahinarslan А, Cengel А, Okyay К, et al. B-type natriuretic peptide and extent of lesion on coronary angiography in stable coronary artery disease. Cor. Art Dis. 2005;16:225-29.
Downloads
Download data is not yet available.